GSK’s Promacta Gets ODAC Nod Despite Concerns Of Off-Label, Long-Term Use
Executive Summary
Despite concerns over off-label use of GlaxoSmithKline's Promacta, FDA's Oncologic Drugs Advisory Committee unanimously backed the drug for short-term use, voting 16-0 that the clinical data demonstrate a favorable risk-benefit ratio
You may also be interested in...
Amgen’s Nplate Has First Mandatory Patient Registration Under REMS
The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients
Amgen’s Nplate Has First Mandatory Patient Registration Under REMS
The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients
With Promise Of Post-Market Safety Studies, Panel Backs Amgen’s Nplate
FDA's new authority to require post-market studies under the FDA Amendments Act could be the ticket to approval for Amgen's platelet producer Nplate (romiplostim)